Androgen-deprivation Therapy

ADT for up to 36 Months Not Associated With Cognitive Decline

ADT for up to 36 Months Not Associated With Cognitive Decline

By

The long-term use of androgen deprivation therapy (ADT) for up to 36 months does not appear to be associated with cognitive decline in patients with prostate cancer.

Hsp90 Inhibition Overcomes Hormone Resistance in Some Aggressive Prostate Cancers

By

The second-generation hsp90 inhibitor onalespib may be beneficial for men with prostate cancer that no longer responds to androgen deprivation therapy

In mCRPC, Docetaxel Active After Antiandrogen Therapy

By

A total of 40% of patients with mCRPC treated with docetaxel after abiraterone achieved at least a 50% reduction in PSA, according to a study presented at the 2016 Genitourinary Cancers Symposium.

GnRH Agonists Associated With Higher Adverse Effect Risk vs Orchiectomy

By

Gonadotropin-releasing hormone agonist (GnRHa) therapy is associated with increased risks of numerous clinically relevant adverse events compared with orchiectomy.

Intermittent ADT for Prostate Cancer Does Not Reduce Long-term Effects

By

A study compared the number of adverse events caused by both intermittent and continuous androgen-deprivation therapy (ADT) for prostate cancer.

Medical Records Reveal Alzheimer Diagnoses Higher Among Patients Receiving ADT for Prostate Cancer

By

In a study that demonstrates the emerging technique of extracting biomedical data from ordinary patient medical records, a nearly 2-fold increase was seen in the rate of Alzheimer disease diagnoses among men with prostate cancer who received ADT.

Androgen deprivation therapy may lead to cognitive impairment in prostate cancer patients

By

Men who are receiving androgen deprivation therapy (ADT) have an increased chance of experiencing impaired cognitive function.

Prostate cancer medications linked to increased heart-related deaths in some men

By

Some prostate cancer medications are linked to an increased risk of dying from heart-related causes in men with congestive heart failure or with a history of prior heart attacks.

Androgen deprivation therapy may increase risk of cardiac-related death in patients with cardiac issues

Androgen deprivation therapy may increase risk of cardiac-related death in patients with cardiac issues

Men who were treated with androgen deprivation therapy for prostate cancer have a three times increased risk of cardiac problems.

Primary androgen deprivation ineffective for most early prostate cancer

By

In a study of men with early stage prostate cancer, those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.

Key cellular pathway in prostate cancer identified

By

The protein SPOP, which is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer.

Androgen deprivation for prostate cancer can harm kidneys

By

Androgen deprivation therapy (ADT) was significantly associated with an increased risk for acute kidney injury in a large study of men with nonmetastatic prostate cancer.

Prostate cancer survival may be compromised by on-and-off treatment approach

By

Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.

Men at high skeletal risk prior to prostate cancer hormone therapy likely to have more fractures

By

Men with a high risk of bone fracture who are receiving long-term ADT for prostate cancer have a higher fracture incidence after their treatment is completed. Also, men who experienced a fracture had a 1.38-fold higher mortality risk than those who did not.

Zytiga approved for metastatic prostate cancer

The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.

Androgen deprivation may be harmful for some prostate cancer

Androgen deprivation may be harmful for some prostate cancer

May accelerate progression in cases of PTEN-loss induced high-grade prostatic intraepithelial.

New drugs, new thinking for prostate cancer

By

Optimal treatment of older patients with recurrent prostate cancer now involves more of a decision process than in the past, say the authors of a review article in the journal Drugs & Aging.

Some breast cancers may respond to anti-androgen drug

By

Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.

Annual report highlights 2012 cancer advances

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.

Radiotherapy after prostatectomy has long-term benefits

Administering radiotherapy after prostatectomy helped nearly two-thirds of users in a recent study remain free of prostate cancer after 10 years.

Noninvasive assay monitors treatment response in patients with metastatic prostate cancer

By

Certain analyses of cancer cells isolated from the blood could guide decisions about the ideal treatment for a patient with metastatic prostate cancer who has stopped responding to initial therapy.

Signaling in prostate tumors indicates responsiveness

Signaling in prostate tumors indicates responsiveness

State of androgen receptor signaling may help determine best treatment.

Survival similar for on/off androgen deprivation vs continuous therapy

Intermittent androgen deprivation was just as effective as continuous therapy in overall survival, and improved some quality-of-life factors.

Tamoxifen soothes effects of prostate cancer treatment

The anti-estrogen tamoxifen appears to suppress gynecomastia and breast pain in men undergoing androgen-suppression therapy for prostate cancer.

PSA era sees improved overall survival rates in prostate cancer

Overall survival rates have improved for men with prostate cancer following the introduction of PSA screening, particularly for African Americans.

Calcium and vitamin D may hurt, not help, in prostate cancer

Calcium and/or vitamin D supplementation at commonly recommended doses does not prevent bone loss from androgen-deprivation therapy.

Protein keeps prostate cancer growing despite hormone therapy

The protein paxillin can regulate signals that lead to the creation of prostate cancer cells even in the absence of tumor-nurturing hormones.

BMD loss occurs early in androgen deprivation therapy

BMD loss occurs early in androgen deprivation therapy

Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer.

New drugs change treatment landscape for advanced prostate cancer

Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.

Experts have conflicting views on CV risk in prostate cancer therapy

A meta-analysis provides reassurance that androgen deprivation therapy is not associated with an increased risk of cardiovascular deaths, but other specialists warn against ignoring this risk.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs